A Note of Appreciation, A Mark of Recognition | Medicilon Supports Partner Tasly in Obtaining Clinical Trial Approval for TSL2402 Tablets

Recently, Tianjin Tasly Saint Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tasly Pharmaceutical Group Co., Ltd. (Stock Code: 600535), received the Notice of Approval for Drug Clinical Trial (No. 2026LP02559) for TSL2402 Tablets issued by the National Medical Products Administration (NMPA), authorizing the initiation of clinical trials for the drug.As Tasly’s partner, Medicilon has received […]